The IHE releases Towards a Framework for Biosimilar Evidence and Knowledge Exchange
The Institute of Health Economics (IHE) has released Towards a Framework for Biosimilar Evidence and Knowledge Exchange, a summary report following an IHE Biosimilars Forum held April 23, 2017 in Ottawa, Ontario.
This forum was held in conjunction with the 2017 Annual Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium. This is the third IHE Forum on biologics/biosimilars that has been conducted, with the first held on May 29, 2014, and the second on October 6, 2016.
The purpose of this forum was to gather key stakeholders from the public and private sectors, as well as clinicians, academics, and patient and provider associations, in order to:
- Review the experience of NHS Scotland and lessons for Canada with the development and utilization of a National Biosimilars Prescribing Framework.
- Identify an approach to knowledge exchange that will enable a common view and shared agreement amongst patients and clinicians regarding appropriate and intended use of biosimilars.
A number of conclusions emerged from the meeting:
- A therapeutic area-specific approach is required: There is a need to consider disease or therapeutic areas separately and to develop approaches tailored to each.
- There is a need for defined leadership and process: There is benefit from developing one defined process with identified leadership from a neutral and trusted organization, to promote a coordinated, disease-specific, strategic approach to biosimilars for Canada.
- The “product” is more than the molecule: Biologics manufacturers and providers have worked together to develop key infrastructure supports such as clinic and product delivery services, access to medications, education, adherence resources, and outcomes monitoring and reporting. There is a need to better document those supports, and to develop incentives to ensure that appropriate and high quality packages of care are offered and delivered to patients.
- We should strive for healthy biologic agent co-existence and competition: A well-performing competitive market will help facilitate continued product innovation and support sustainable cost-savings over time.
- Therapeutic outcomes monitoring is essential: There is a need to be very deliberate about monitoring and reporting on outcomes achieved with therapies as provider and patient confidence in biosimilars will positively correlate with feedback.
Next Steps Include YOU!
SHARE your ideas NOW! Impact Policy. Join the IHE Life Sciences Open Innovation Platform™.
The Institute of Health Economics has launched an online “ideasourcing” platform, called the IHE Life Sciences Open Innovation Platform™, to obtain input from a broad pan-Canadian community on key issues and topics related to life sciences policy. Earlier this year, the platform hosted a series of online campaigns to gather information from a range of stakeholders on policy questions that served as input into the April 2017 IHE Biosimilars Forum. In order to inform actions to address the conclusions identified in the summary report announced today, this platform will serve as a living medium through which on-going dialogue on the development of biosimilars policy can continue. An interim report will be created August 1st, with leading ideas, to be shared with policy, industry, and community Leaders.
How it Works:
Then logon and:
- SHARE your ideas - Post early and often to give time for others to comment and contribute.
- VOTE and/or ADD to the ideas of others.
- REPEAT – Check back often as the platform is ALIVE, with new comments and ideas every day.
- Strengthening Models of Care: How can the introduction of biosimilars improve the resources available to patients and providers?
- Approach to Biosimilar Introduction: How do we develop a Canadian approach to biosimilar introduction, including a framework to assess the evidence, what outcomes do we need to track and report on to provide confidence and comfort to stakeholders, and how do we best capture and liberate data?
- Active and Sustained Competition: What are the most appropriate models to encourage healthy competition in a post patent biologics market, is there any role or requirement for payer policy to manage utilization of biosimilars to achieve objectives, and how do we measure and evaluate the value of therapies and supporting services?
- Education and Experience: What type of educational material is required, who should produce it, and what are the best vehicles for dissemination?
- Stakeholder Engagement: What are the best mechanisms for continuous stakeholder engagement and consultation, and how can public and private payers best collaborate for a consistent, responsive, and transparent pan-Canadian approach to biosimilar policy?
For more information, or to download the summary report, please click the following link:
Director, Marketing and Communications
Institute of Health Economics